Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Study data from Charite University, Institute of Clinical Pharmacology update understanding of adverse drug reactions
March 2nd, 2008
A new study, 'Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol,' is now available. According to recent research published in the Journal of Clinical Psychopharmacology, "The analgesic drug tramadol is bioactivated by CYP2D6 to the opioid receptor agonist O-desmethyltramadol. Case reports indicated that carriers of the CYP2D6 gene duplication may be at high risk for opioid adverse events." "However, the effects of the CYP2D6 duplication on kinetics and dynamics of tramadol have not been systematically studied. Pharmacokinetics and effects were monitored after a single dose of 100 mg racemic tramadol in 11 carriers of...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-02)
|
